Thousands tracked to see if synthetic artery grafts hold up over time

NCT ID NCT07161583

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This registry follows 1000 people who received Advanta VXT or Flixene grafts to repair peripheral arteries. Researchers will check how well the grafts stay open and how often serious problems like amputation or repeat surgery occur. The goal is to confirm these devices are safe and work well over the long term.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Advanta VXT and Flixene vascular grafts (synthetic tubes used to replace or repair damaged arteries)
What this could lead to
If successful, this registry could confirm that these grafts are safe and effective for long-term use, helping doctors choose better options for peripheral artery disease.
What could go wrong
This is an observational registry, not a controlled trial, so results may not prove cause and effect. Grafts can still fail or cause complications like infection or blockage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de Brest

    RECRUITING

    Brest, Brittany Region, France

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.